biostudies-literatureVijenthira ANCI NIH HHS5949-5956https://www.ebi.ac.uk/biostudies/studies/S-EPMC11629178biostudies-literatureUnknown8(23)<h4>Abstract</h4>Clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic lymphocytic leukemia (CLL) has not been extensively characterized. The objective of this study was to describe the prevalence of myeloid CHIP (M-CHIP) in patients with CLL, and to determine its association with time to first treatment (TTFT) and overall survival (OS). We retrospectively analyzed data from patients participating in a prospective CLL database at the Dana-Farber Cancer Institute who had standard-of-care targeted 95-gene next-generation sequencing (NGS) performed. A schema was devised to classify mutations as M-CHIP related. M-CHIP was analyzed as a binary (present/absent) and categorical (≥2 vs 1 vs 0 mutations) predictor. We included 966 patients (median age at time of NGS, 65 yeBlood advancesMyeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.PMC11629178R01 CA258924Fernandes SMGetz GDavids MSRen YVijenthira AFardoun RVolpe VOKnisbacher BABrown JRGibson CJMikhaleva MMartindale SPTyekucheva SWu CJSantos Azevedo RSekar AHahn CKfalseMyeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.<h4>Abstract</h4>Clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic lymphocytic leukemia (CLL) has not been extensively characterized. The objective of this study was to describe the prevalence of myeloid CHIP (M-CHIP) in patients with CLL, and to determine its association with time to first treatment (TTFT) and overall survival (OS). We retrospectively analyzed data from patients participating in a prospective CLL database at the Dana-Farber Cancer Institute who had standard-of-care targeted 95-gene next-generation sequencing (NGS) performed. A schema was devised to classify mutations as M-CHIP related. M-CHIP was analyzed as a binary (present/absent) and categorical (≥2 vs 1 vs 0 mutations) predictor. We included 966 patients (median age at time of NGS, 65 ye2024-01-01T00:00:00Z2024 Dec2025-04-19T14:37:02.587Z2025-04-19T14:37:02.587ZS-EPMC116291783932142110.1182/bloodadvances.2024013414